论文部分内容阅读
目的探讨CIK细胞免疫治疗对晚期恶性肿瘤患者免疫功能的影响。方法选取56例化疗后接受CIK治疗的晚期恶性肿瘤患者,采集其外周血提取单个核细胞(PBMC),经体外扩增培养CIK细胞进行回输,隔天1次,4次为1个疗程,共3个疗程。检测其治疗前后外周血T细胞亚群比例的变化及生活质量(QOL)改善情况,酶联免疫吸附试验(ELISA)检测其治疗前后外周血中细胞因子白细胞介素-2(IL-2)、干扰素-γ(IFN-γ)水平变化。结果治疗后外周血中T细胞亚群CD3+、CD4+T细胞数、CD4+/CD8+比例及IL-2、IFN-γ水平明显高于治疗前(P均<0.05),CD8+T细胞数治疗后较治疗前降低,但差异未见统计学意义(P>0.05)。生活质量较治疗前明显提高,改善率为69.6%(P<0.05)。结论 CIK细胞免疫治疗可增强晚期恶性肿瘤患者的免疫功能,提高其生活质量,可成为其较为理想的治疗手段。
Objective To investigate the effect of CIK cell immunotherapy on immune function in patients with advanced malignant tumors. Methods Fifty-six patients with advanced malignant tumor who were treated with CIK after chemotherapy were enrolled. Peripheral blood was collected to collect mononuclear cells (PBMCs). CIK cells were cultured and expanded in vitro for 1 week. Four times for one course of treatment, A total of 3 courses. The changes of T lymphocyte subsets and quality of life (QOL) in peripheral blood were measured before and after treatment. The levels of interleukin 2 (IL-2), interleukin-2 Interferon-γ (IFN-γ) levels change. Results After treatment, the levels of CD3 +, CD4 + T cells, CD4 + / CD8 + and IL-2 and IFN-γ in T lymphocyte subsets were significantly higher than those before treatment (all P <0.05) Lower than before treatment, but the difference was not statistically significant (P> 0.05). The quality of life was significantly higher than before treatment, the improvement rate was 69.6% (P <0.05). Conclusion CIK cell immunotherapy can enhance the immune function and improve the quality of life of patients with advanced malignant tumors, which may be an ideal treatment.